Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.
Profitability
This table compares Lisata Therapeutics and GeoVax Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -116.08% | -90.55% |
| GeoVax Labs | N/A | -743.64% | -394.74% |
Insider and Institutional Ownership
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 50,747.46%. Given GeoVax Labs’ stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Lisata Therapeutics.
Risk and Volatility
Lisata Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.69, suggesting that its stock price is 269% more volatile than the S&P 500.
Valuation and Earnings
This table compares Lisata Therapeutics and GeoVax Labs”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | $170,000.00 | 66.20 | -$16.59 million | ($1.64) | -0.76 |
| GeoVax Labs | $2.49 million | 0.87 | -$21.47 million | ($11.34) | -0.03 |
Lisata Therapeutics has higher earnings, but lower revenue than GeoVax Labs. Lisata Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Lisata Therapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
